Continued nintedanib in patients with systemic sclerosis‑associated interstitial lung disease

Please find below an animated figure with voiceover that describes the decline in forced vital capacity during the placebo‑controlled SENSCIS trial and the open‑label extension trial SENSCIS‑ON.

Header - Navigation Icon

The SENSCIS and SENSCIS-ON trials were funded by Boehringer Ingelheim International GmbH (BI). The authors meet criteria for authorship as recommended by the International Committee of Medical Journal Editors (ICMJE). The authors did not receive payment for development of this animated figure or the manuscript on which it is based. Julie Fleming and Wendy Morris of FleishmanHillard, London, UK, provided editorial assistance, which was contracted and funded by BI. BI was given the opportunity to review the animated figure and the manuscript for medical and scientific accuracy as well as intellectual property considerations.